On June 6, 2018 Merck Animal Health announced their new RNA Particle (RP) Technology Vaccine Platform first product targeting Pigs, called SEQUIVITY™ which they launched at the 2018 World Pork Expo. [1, 2, 3]
Sequivity™ RNA Particle Technology, is an alphavirus replicon vector system, where the platform allows for “Veterinary Prescription” or customised herd-specific “vaccines” [5]. “After receiving the sequence, it is synthesised into RNA and inserted into the SEQUIVITY platform, which generates RNA particles. When injected in the animal, these particles provide instructions to the immune cells to translate the sequence into proteins which act as antigens.” [4]
Merck state that “Millions of doses of the SEQUIVITY vaccine platform have safely been used by veterinarians in swine herds for more than ten years since the USDA first issued the license in 2012.” This is becasue Merck purchased Harrisvaccines who first gained USDA approval in September 2012.